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ABSTRACT
Purpose This is an official interdisciplinary guideline, pub-
lished and coordinated by the German Society of Gynaecology
and Obstetrics (DGGG), the Austrian Society of Gynaecology
and Obstetrics (OEGGG) and the Swiss Society of Gynaecology
and Obstetrics (SGGG). The guideline was developed for use
in German-speaking countries and is backed by the German
Society of Anaesthesiology and Intensive Medicine (DGAI),
the Society of Thrombosis and Haemostasis Research (GTH)
and the German Association of Midwives. The aim is to pro-
vide a consensus-based overview of the diagnosis and man-
agement of peripartum bleeding obtained from an evaluation
of the relevant literature.
Methods This S2k guideline was developed from the struc-
tured consensus of representative members of the various
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professional associations and professions commissioned by
the Guideline Commission of the DGGG.
Recommendations The guideline encompasses recommen-
dations on definitions, risk stratification, prevention and man-
agement.
ZUSAMMENFASSUNG
Ziel Erstellung einer offiziellen interdisziplinären Leitlinie, pu-
bliziert und koordiniert von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG), der Österreichischen
Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) und
der Schweizerischen Gesellschaft für Gynäkologie und Ge-
burtshilfe (SGGG). Die Leitlinie wurde für den deutschsprachi-
gen Raum entwickelt und wird von der Deutschen Gesell-
schaft für Anästhesiologie und Intensivmedizin (DGAI), der
Gesellschaft für Thrombose- und Hämostaseforschung (GTH)
und dem Deutschen Hebammenverband mitgetragen. Das
Ziel dieser Leitlinie ist es, durch die Evaluation der relevanten
Literatur einen konsensbasierten Überblick über die Diagnos-
tik und das Management der peripartalen Blutung zu geben.
Methoden Diese S2k-Leitlinie wurde durch einen strukturier-
ten Konsens von repräsentativen Mitgliedern verschiedener
Fachgesellschaften und Professionen im Auftrag der Leitlini-
enkommission der DGGG entwickelt.
Empfehlungen Es werden Empfehlungen zur Definition, Risi-
kostratifizierung, Prävention und Management gegeben.I Guideline Information
Guidelines programme of the DGGG, OEGGG
and SGGG
Information on the guidelines programme is available at the end
of the guideline.
Citation format
Peripartum haemorrhage, diagnosis and therapy. Guideline of the
DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 015/
063, March 2016). Geburtsh Frauenheilk 2018; 78: 382–399▶ Table 1 Authors and representativity of the guideline group: participation
Author
Mandate holder
DGGG working group/AWMF/no
Lead author and/or coordinating author:
PD Dr. med. Dietmar Schlembach German Society of Gynaecology an
[DGGG])
Other lead authors:
Prof. Dr. med. Hanns Helmer Austrian Society of Gynaecology a
[OEGGG])
Prof. Dr. med. Wolfgang Henrich German Society of Gynaecology an
Prof. Dr. med. Christian von Heymann German Society of Anaesthesiolog
und Intensivmedizin e.V. [DGAI])
Prof. Dr. med. Franz Kainer German Society of Gynaecology an
Prof. Dr. med. Wolfgang Korte Society of Thrombosis and Haemo
[GTH])
Prof. Dr. med. Maritta Kühnert German Society of Gynaecology an
Dr. med. Heiko Lier German Society of Anaesthesiolog
PD Dr. med. Holger Maul Deutsche Society of Gynaecology
Prof. Dr. med. Werner Rath German Society of Gynaecology an
Susanne Steppat German Society of Midwives (Deut
Prof. Dr. med. Daniel Surbek Swiss Society of Gynaecology andO
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PowerPoint presentations and a summary of the conflicts of inter-
est of all the authors is available on the AWMF homepage under:
http://www.awmf.org/leitlinien/detail/ll/015-063.html
Guideline authors
The following professional and scientific societies/working
groups/organisations/associations have stated their interest in
contributing to the compilation of the guideline text and partici-
pating in the consensus conference and nominated representa-
tives to attend the consensus conference (▶ Table 1).of the target user group.
n-AWMF professional societies/organisations/associations
d Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V.
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nd Obstetrics (DGGG)
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AAGBI Association of Anaesthetists of Great Britain
and Ireland
AFE amniotic fluid embolism
AMSTL active management of third stage of labour
aPTT activated partial thromboplastin time
AT/AT III antithrombin/antithrombin III
BGA blood gas analysis
BMI body mass index
BL blood loss
BW body weight
CMACE Centre for Maternal and Child Enquiries
DDAVP desmopressin
DIC disseminated intravascular coagulation
ESA European Society of Anaesthesiology
FFP fresh frozen plasma
Hb haemoglobin
HR heart rate
Hct haematocrit
IM intramuscular
INR international normalized ratio
IU international unit
IUFD intrauterine fetal death
IV intravenous
MAP mean arterial pressure
MRI magnetic resonance imaging
NICE National Institute for Health and Care Excellence
OAA Obstetric Anaesthetists Association
OR odds ratio
PCC prothrombin complex concentrate
POC point of care
PPH postpartum haemorrhage
rFVIIa recombinant factor VII a
RBC red blood cell concentrate
ROTEM rotational thromboelastometry
RRsys/RRdia RR systolic/RR diastolic
s/p status post
TEG thromboelastography
US ultrasound
VET viscoelastic test
WHO World Health OrganisationII Guideline Application
Purpose and objectives
This aim of this guideline is to create an interdisciplinary (includ-
ing anaesthesiologists and intensive care physicians, obstetri-
cians, midwives, puerperal care nursing staff) management and
treatment algorithm for the management of peripartum haemor-
rhage (diagnosis, risk selection, therapy).384 SchlembaThe guideline was compiled to improve the knowledge of all
persons involved in the care of pregnant women and women in
childbed who experience or have an increased risk of haemor-
rhage.
The aim was to improve the care of affected patients and re-
duce problems in the management of PPH.
Targeted areas of patient care
▪ Outpatient care
▪ Primary/specialised care
▪ Inpatient care
Target user groups/target audience
This guideline is aimed at the following groups of people:
▪ gynaecologists/obstetricians in private practice (non-hospital
based)
▪ hospital-based gynaecologists/obstetricians
▪ anaesthesiologists and intensive care physicians
▪ haemostasis specialists and lab clinicians
▪ interventional radiologists
▪ midwives
▪ nursing staff (surgery, anaesthesiology, intensive care unit,
obstetrics/postpartum care)
Adoption of the guideline and period of validity
The validity of this guideline was confirmed in September 2015 by
the respective boards/representatives of the participating profes-
sional societies/working groups/organisations/associations, by
the board of the DGGG and the DGGG Guideline Commission
and by the SGGG and the OEGGG, which constitutes approval of
the entire contents of the guideline. This guideline is valid from
May 1, 2016 through to March 31, 2019. Because of the contents
of this guideline, the above-mentioned period of validity is only an
estimate. The guideline can be updated earlier if urgently re-
quired. Should the guideline continue to reflect the current level
of scientific knowledge, then the guidelineʼs period of validity can
be extended.III Methodology
Basic principles
The methodology used to compile this guideline is determined by
the class assigned to the guideline. The AWMF Guidance Manual
(version 1.0) has set out the respective rules and requirements.
Guidelines are differentiated into lowest (S1), intermediate (S2)
and highest (S3) class. The lowest class consists of a set of recom-
mendations for action compiled by a non-representative group of
experts. In 2004 the S2 class was divided into two subclasses: a
systematic evidence-based (S2e) subclass and a structural con-
sensus-based subclass (S2k). The highest S3 class combines both
approaches.
This guideline is classified as: S2kch D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 382–399
Grading of recommendations
The grading of evidence and the grading of recommendations
was not envisaged for S2k class guidelines. Individual statements
and recommendations are differentiated by syntax, not by sym-
bols (▶ Table 2).▶ Table 2 Grading of recommendations.
Description of grade of recommendation Syntax
Strong recommendation, highly binding must/must not
Recommendation, moderately binding should/should not
Open recommendation, not binding may/may not
▶ Table 4 The 4 Ts: causes of PPH [6,16,30–32].
Tone
(uterine
atony)
Uterine distension
(multiparity, polyhydramnios, fetal macrosomia)
Tocolytics
Precipitate labour or prolonged labour
(Prolonged) oxytocin augmentation
Chorioamnionitis
Uterine fibroids
Tissue
(placenta)
Retained placenta
Abnormally invasive placentaThe above classification of recommendations reflects the eval-
uated evidence and the clinical relevance of the studies on which
the recommendations are based and various measures/factors
which did not appear in the grading of evidence, such as the
choice of patient population, intention-to-treat or per-protocol-
outcome analyses, medical or ethical behaviour towards patients,
country-specific application, etc.
Statements
Expert statements included in this guideline which are not recom-
mendations for action but simple statements of fact are referred
to as statements. It is not possible to provide a level of evidence
for these statements.
Achieving consensus and level of consensus
During structured consensus-based decision-making (S2k/S3 lev-
el), the authorised representatives present at the respective ses-
sion vote on draft Statements and Recommendations. Discussions
during the session may lead to significant changes in the wording
of Statements and Recommendations. At the end of the session,
the extent of agreement (level of consensus) is determined based
on the number of participants (▶ Table 3).▶ Table 3 Classification of extent of agreement in consensus decision-
making.
Symbol Level of consensus Extent of agreement
in percent
+++ Strong consensus > 95% of participants agree
++ Consensus > 75–95% of participants agree
+ Majority agreement > 50–75% of participants agree
– No consensus < 50% of participants agree
Schlembach D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 382Expert consensus
As the name implies, this refers to consensus decisions taken with
regard to specific Recommendations/Statements without a pre-
vious systematic search of the literature (S2k) or when evidence
is lacking (S2e/S3). The term “Expert Consensus” (EC) used here
is synonymous with the terms “Good Clinical Practice” (GCP) and
“Clinical Consensus Point” (CCP) used in other guidelines. The lev-
el of recommendation is graded as previously described in the
Chapter Grading of recommendations but only semantically
(“must”/“must not” or “should”/“should not” or “may”/“may
not”) and without using symbols.IV Guideline
1 Introduction
The incidence of postpartum haemorrhage (PPH) is continually in-
creasing [1–5], mostly because of the increase in uterine atony
and disorders of placental implantation and increased rates of sur-
gical vaginal delivery and Caesarean sections and the consequent
increase in primary blood loss and, in the case of Caesarean sec-
tion, the increased PPH rates in subsequent pregnancies [2, 6–
11].
In the western world, life-threatening postpartum haemor-
rhage occurs in approximately 2 of 1000 births and severe mater-
nal morbidity occurs in around 3 of 1000 births [12–22]. PPH is(morbidly adherent placenta, placenta accreta/
increta/percreta)
Placental remnants
Trauma Vulvovaginal injury
Cervical tear
Episiotomy/perineal tear
Uterine rupture
Uterine inversion
Thrombin
(coagulo-
pathy)
Pregnancy-induced:
Thrombocytopenia (HELLP syndrome, disseminated
intravascular coagulation [DIC]) (e.g. in pre-eclampsia,
intrauterine fetal death [IUFD], placental abruption,
amniotic fluid embolism)
Other:
vonWillebrand disease, plasmatic coagulopathies,
thrombopathy, coagulation factor deficiencies
(loss, consumption, dilution)
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▶ Table 5 Risk factors for PPH [16,23,37–39].
Odds ratio or range
Blood loss > 500ml > 1000ml
Sociodemographic risk factors
▪ obesity (BMI > 35) 1.6
▪ maternal age (≥ 30 years) 1.3–1.4 1.5
Obstetric risk factors
▪ placenta praevia 4–13.1 15.9
▪ premature placental separation 2.9–12.6 2.6
▪ retained placenta 4.1–7.8 11.7–16.0
▪ prolonged expulsion of the placenta 7.6
▪ pre-eclampsia 5.0
▪ grandmultiparity 2.3–4.5 2.6
▪ s/p PPH 3.0–3.6
▪ fetal macrosomia 1.9–2.4
▪ HELLP syndrome 1.9
GebFra Science | Guidelinethe cause of approximately 30% of all maternal deaths in the Third
World and 13% of maternal deaths in industrialised countries [21].
The majority of maternal deaths from PPH could be avoided;
major substandard care was present in 60–80% of all cases [1,
20,21,23–25]. What is especially alarming is that a visual estima-
tion of blood loss during delivery results in the extent of bleeding
being underestimated by 30–50% [26–29].
In Britain and America, the causes of PPH have been summa-
rized as the “4 Ts”. (Combinations of these causes are the rule.)
(▶ Table 4).
The main risk management problems in the management of
PPH are [1,24,33,34]:
▪ Delayed diagnosis and/or therapy due to underestimation of
the actual amount of blood lost
▪ Delayed provision of blood or coagulation products
▪ Lack of or failure to follow simple instructions
▪ Lack of adequate training or advanced training
▪ Poor communication within the interdisciplinary team
▪ Deficits in the organisational structure
▪ Delay in initiating treatment standards
2 Definitions▪ Polyhydramnios 1.9
▪ (prolonged) oxytocin augmentation 1.8
▪ labour induction 1.3–2 2.1–2.4
▪ protracted labour 1.1–2
Surgical risk factors
▪ emergency Caesarean section 3.6
▪ elective Caesarean section 2.5
▪ operative vaginal delivery 1.8–1.9
▪ episiotomy 1.7–2.21 2.07
▪ perineal tear 1.7 2.5
Other risk factors
▪ antepartum haemorrhage 3.8
▪ von Willebrand disease 3.3
Consensus-based Recommendation 2.E1
Expert consensus Level of consensus +++
The following definition of PPH is proposed (for German-speaking areas):
▪ Blood loss of ≥ 500ml following vaginal delivery
▪ Blood loss of ≥ 1000ml following Caesarean section3 Risk Stratification and Prevention
A complete and detailed patient history, ultrasound examination
during antenatal appointments, assessment of the patientʼs risk
of bleeding, presentation to the maternity hospital, and prepara-
tions for increased blood loss could reduce patientsʼ risk of PPH
[35].Consensus-based Recommendation 3.E2
Expert consensus Level of consensus +++
Location and structure of the placenta must be documented during ultra-
sound examination in the 2nd trimester. If necessary, patients with low-
lying placenta should undergo an additional ultrasound scan to screen for
vasa praevia and the findings should be documented [36].
Consensus-based Recommendation 3.E3
Expert consensus Level of consensus +++
An implantation disorder should be considered in women with a high-risk
history (previous operations) or findings (placenta praevia) which indicate
high risk.
386 Schlemba3.1 Risk stratification and risk factors which facilitate
peripartum/postpartum haemorrhage (▶ Table 5)▪ anaemia (< 9 g/dl) 2.2
▪ fever during delivery 2Other risk factors include precipitous birth, high maternal parity,
fibroids and uterine malformations [39].
Caution: The majority of patients who develop PPH do not
have identifiable risk factors [39].
3.2 Sonographic risk stratification
(placentation disorders)Consensus-based Recommendation 3.E4
Expert consensus Level of consensus +++
Patients with suspected abnormally invasive placentamust present early to
a suitable maternity hospital where they must be treated by a multidisci-
plinary team (“by the best team at an optimal point in time”) [20,40].
ch D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 382–399
Consensus-based Statement 4.S1
Expert consensus Strength of consensus +++
Alongside general interventions (such as stabilising the patientʼs haemo-
dynamic status), causal treatment of PPH includes medical therapy and/or
surgical procedures that must be performed quickly, in a coordianted andThe diagnostic value of MRI has not yet been convincingly demon-
strated in these cases [41,42], but MRI examination could provide
additional information when findings are ambiguous [42,43].
3.3 Prevention
3.3.1 Active management of third stage of labour
3.3.1.1 Active management after vaginal deliveryConsensus-based Recommendation 3.E5
Expert consensus Level of consensus +++
After the infant has been born and commenced breathing, oxytocin (Syn-
tocinon® 3–5 IU slow IV infusion) must be administered for PPH prevention
[44].
Consensus-based Recommendation 3.E6
Expert consensus Level of consensus ++
Immediate clamping of the umbilical cord at birth and controlled cord
traction have no impact on reducing postpartum haemorrhage and should
not be carried out.
often simultaneous manner [45–47].3.3.1.2 Prevention of PPH during Caesarean sectionConsensus-based Recommendation 3.E7
Expert consensus Level of consensus +++
PPH prophylaxis must be administered as in vaginal delivery.Prophylaxis can consist of administering either oxytocin (Syntoci-
non® 3–5 IU by short infusion [or slow IV infusion]) or carbetocin
(Pabal® 100 µg) by short infusion or slow IV infusion.
3.3.2 If risk factors are presentConsensus-based Recommendation 3.E8
Expert consensus Level of consensus +++
If risk factors are present, the following measures must be taken:
▪ Adequate venous access for every woman in labour, adequate intra-
venous access in case of complications of bleeding
▪ Uterotonics must be available (oxytocin, e.g. Syntocinon®), prostaglan-
dins (e.g. sulprostone: Nalador®), misoprostol (Cytotec®, off-label use)
▪ Check logistics:
– Check availability of emergency laboratory tests (complete blood
count, blood gas analysis [BGA], aPTT, prothrombin time [PT] or INR,
antithrombin [AT], fibrinogen, possibly thromboelastography or
thromboelastometry [ROTEM])
– Obstetrician and anaesthesiologist must be on site, experienced
obstetrician and experienced anaesthesiologist on call
– Check availability of blood products: cross-matching, ordering of
packed red blood cells, fresh frozen plasma and platelets
– Check availability of haemostatic agents (tranexamic acid [Cyclokap-
ron®], fibrinogen [Haemocomplettan®], factor XIII [Fibrogammin®],
recombinant activated factor VII a [rFVIIa, NovoSeven®, off-label
use]).
Schlembach D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 3824 Management of PPH4.1 Procedures
▪ Measure blood loss! (Caution: blood loss in bandages, etc.)
▪ Rapid diagnosis of the cause of bleeding (4 Tʼs):
– Estimation of uterine tone
– Check whether placenta is complete (ultrasound, manual or
instrumental examination)
– Exclude vulvovaginal trauma by speculum examination
– Administer uterotonics (in case of atony) and tranexamic
acid to treat critical blood loss
– Uterine compression
▪ Call in anaesthesiologist (multidisciplinary team) at an early
stage
▪ Drug therapy and/or surgical procedures, depending on the
cause of bleeding
▪ Control vital signs, consider timely invasive monitoring
▪ Initial volume substitution to maintain normovolaemia: cristal-
loids, in exceptional cases (e.g. acute haemorrhage and hae-
modynamic instability) colloidal solutions [48]
▪ Cross-matching of blood, emergency laboratory tests (incl. full
blood count, coagulation)
▪ Order packed red blood cells and fresh frozen plasma, provide
blood products if required (delivery room, operating theatre)
▪ Coagulation factors, especially fibrinogen
▪ Other haemostatic agents (e.g. desmopressin), factor XIII or
rFVIIa if necessary
▪ Intensive monitoring of patient during hospital stay, consider
invasive monitoring
▪ Timely surgical intervention when conservative measures fail
(see below for appropriate procedures)
Measuring blood loss
One of the cardinal problems which occur not only when defining
but primarily when diagnosing and treating PPH is that the extent
of postpartum blood loss is rarely measured and is known to be
underestimated by 30–50% if assessment is done on a purely vi-
sual basis [35,49].Consensus-based Recommendation 4.E9
Expert consensus Level of consensus +++
Collecting all blood-soaked pads, bedding, linens and significant coagulum
is strongly recommended.
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Consensus-based Recommendation 5.E11
Expert consensus Level of consensus ++
Therapy:
After vaginal delivery
▪ uterotonics, tranexamic acid if required
▪ if necessary, manual separation of the placenta followed by curettage
▪ if necessary, uterine tamponade as a bridging procedure
▪ laparotomy and other surgical measures
▪ possibly embolisation
After Caesarean section
▪ uterotonics, tranexamic acid if required
▪ surgical measures
▪ consider embolisation
GebFra Science | Guideline5 General (Emergency) Measures and Diagnosis
to Determine Causes of PPH
5.1 Atony
▪ Diagnosis: increased fundal height; soft slack uterus; usually
intermittent heavy bleeding.
▪ Void the bladder!
▪ Mechanical procedures: uterine massage (endogenous prosta-
glandin formation), bimanual uterine compression (e.g. Hamil-
tonʼs manoeuvre)
▪ Exclude vulvovaginal trauma (by speculum examination and
abdominal US if necessary)
▪ Exclude retained placenta (examine the placenta to ensure it is
complete, sonography)Consensus-based Recommendation 5.E10
Expert consensus Level of consensus +++
Therapy:
After vaginal delivery
▪ uterotonics, tranexamic acid if required
▪ careful curettage in the delivery room or operating theatre if retained
placenta is suspected
▪ uterine tamponade if required
▪ other surgical procedures
▪ consider embolisation
After caesarean section
▪ uterotonics, tranexamic acid if required
▪ surgical procedures
Consensus-based Recommendation 5.E12
Expert consensus Level of consensus ++
Therapy:
The goal is the reposition of the uterus and treatment of the symptoms
of haemorrhagic shock. The following procedures must be carried out
immediately after making the diagnosis in the order stated below:
▪ Stop administration of any uterotonic drug
▪ Call in experienced obstetrician and anaesthesiologist
– Ensure adequate intravenous access, volume substitution
– Make no attempt to remove the placenta (higher blood loss); the
placenta must, where possible (placenta accreta), only be removed
after repositioning [53,54]
– Attempt to reposition the fundus (Johnsonʼs manoeuvre)
▪ If attempts at repositioning are unsuccessful, administer uterine relax-
ants (e.g. nitroglycerin 50 µg IV, betamimetics) and repeat the attempt
to reposition the uterus with Johnsonʼs manoeuvre
▪ If repositioning attempts continue to be unsuccessful→ perform lapa-
rotomy and Huntingtonʼs procedure, simultaneously with Johnsonʼs
manoeuvre if necessary; if attempts are still unsuccessful, perform the
Haultain procedure
▪ Administer uterotonics (e.g. oxytocin) after successful repositioning
▪ Provide antibiotic protection (e.g. cephalosporin or clindamycin)
Consensus-based Recommendation 6.E13
Expert consensus Level of consensus +++
Amaximum of 6 IU undiluted oxytocin can be administered slowly and in-
travenously:
▪ 3–5 IU (1 vial) in 10ml NaCl 0.9% as a single (slow intravenous!) bolus
▪ If necessary, this can be followed by 10–40 IU oxytocin in 500–1000ml
saline as a continuous infusion (dose depends on the clinical situation,
particularly the impact on uterine tone) [16,55].5.2 Implantation disorders
The management of abnormally invasive placenta depends on the
time of diagnosis and type of delivery.
Approach for antenatal diagnosis
If an advanced implantation disorder (placenta increta, percreta)
is diagnosed in the antenatal period, delivery must always be by
Caesarean section.
▪ Extensive findings: Caesarean section with hysterectomy;
alternatively, consider expectant management (e.g. delayed
delivery of placenta)
▪ Focal findings: partial resection of the uterine wall
▪ If necessary carry out interventional radiology with prophylac-
tic occlusion of the internal iliac arteries [50,51]
Approach for intrapartum diagnosis
▪ Vaginal delivery:
– If the placenta fails to separate and bleeding is present: carry
out manual separation of the placenta followed by curettage
with intraoperative ultrasound monitoring, if required [52]
– If severe bleeding from the placental bed persists: carry out
surgical therapy, alternatively embolisation of the uterine
arteries
▪ Caesarean section:
– Do not manipulate the placenta or attempt to separate it
manually
– Perform Caesarean section with hysterectomy or alterna-
tively consider expectant management (e.g. delayed deliv-
ery of placenta)388 Schlemba5.3 Uterine inversion6 Medication and Surgical Measures
to Treat PPH
6.1 Uterotonics
6.1.1 Oxytocin (Syntocinon®) IV (IM if necessary)The onset of action after IV administration (half-life of 4–10min)
is less than one minute or 3–5 minutes following intramuscular
administration (maximum 10 IU).ch D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 382–399
6.1.2 Carbetocin (Pabal®)
The use of carbetocin to treat PPH is currently not yet been suffi-
ciently investigated. The use of carbetocin to treat PPH has been
reported in individual cases.
6.1.3 Methylergometrine (Methergin®)Consensus-based Recommendation 6.E14
Expert consensus Level of consensus +++
Given the range of serious side effects and the fact that better alternatives
are available, the utmost caution is advised when administeringmethyl-
ergometrine to manage postpartum haemorrhage.
Consensus-based Recommendation 6.E15
Expert consensus Level of consensus ++
Methylergometrine should not be administered as an intravenous bolus.
Consensus-based Statement 6.S3
Expert consensus Level of consensus +++
Note:
Because of its delayed onset of action and the availability of better and
approved alternatives, misoprostol is not suitable to treat persistent PPH.
The use of misoprostol to treat moderately persistent PPH after the admin-
istration of oxytocin may be considered (off-label use!). However, the cur-
rent data is still insufficient to make a final recommendation.
Consensus-based Statement 6.S4
Expert consensus Level of consensus +++
6.1.4 ProstaglandinsConsensus-based Recommendation 6.E16
Expert consensus Level of consensus +++
If first-line uterotonics are not effective and patients do not respond to first-
line uterotonics, prostaglandins must be administered immediately [56].
Consensus-based Recommendation 6.E17
Expert consensus Level of consensus +++
Oxytocin receptor agonists and prostaglandins must not be administered
simultaneously.
Consensus-based Statement 6.S2
Expert consensus Level of consensus ++
Note:
Postpartum uterine atony and uterine haemorrhage are life-threatening
pathologies and an urgent indication for the administration of prostaglan-
din derivatives if no other alternatives are available or oxytocin is not effec-
tive, until patients can receive obstetric/gynaecological treatment. In this
situation the side effects and contraindications must be carefully consid-
ered (benefits and drawbacks weighed up). Close haemodynamic moni-
toring is necessary when prostaglandin derivatives are administered.
Note:
Postpartum uterine atony and uterine haemorrhage are life-threatening
pathologies and the administration of misoprostol is urgently indicated if
no other alternatives are available, until patients can receive obstetric/
gynaecological treatment. In this context the side effects and contraindi-
cationsmust be carefully considered (benefits and drawbacksweighed up).
Close haemodynamic monitoring is essential when misoprostol is adminis-
tered.
Consensus-based Statement 6.S5
Expert consensus Level of consensus +++
The intramyometrial application of sulprostone (e.g. to the uterine fundus
in cases with caesarean section) is contra-indicated [56].6.1.4.1 Sulprostone (Nalador®)
Dosage:
▪ 1 vial = 500 µg in 500ml solution administered via an infusion
pump
▪ Initial dose: 100ml/h, up to a maximum of 500ml/h if required
▪ Maintenance dose: 100ml/h
▪ Maximum dose 1000 µg/10 hours (2 vials)
▪ Maximum daily dose 1500 µg (3 vials)Schlembach D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 3826.1.4.2 Misoprostol (Cytotec®)
Dosage: 800–1000 µg misoprostol administered rectally or
600 µg administered orally [57–60].
A Cochrane meta-analysis showed that oxytocin infusion was
more effective as a first-line therapy than the administration of
misoprostol and additionally had fewer side effects. When used
after prophylactic uterotonics, misoprostol and oxytocin were
equally effective [61].6.1.4.3 Intrauterine application of prostaglandins7 Uterine Tamponade
The objective of uterine cavity tamponade is twofold: to treat PPH
(i.e., to achieve definitive haemostasis) and as a “bridging” mea-
sure (i.e., to achieve temporary haemostasis and haemodynamic
stabilisation and allow other measures [surgical or interventional
radiology] to be put in place) [62–64]. In addition to other sec-
ond-line treatment strategies, uterine tamponade can signifi-
cantly reduce the rate of emergency hysterectomies [65,66].
In addition to tamponade strips, there are a number of differ-
ent balloon tamponade systems available for uterine tamponade;
their efficacy has been described in various publications and their
use has the advantage of allowing the early detection of persistent
bleeding [64,67–73].389–399
Consensus-based Recommendation 7.E18
Expert consensus Level of consensus ++
▪ Parallel administration of uterotonics
▪ Vaginal examination/ultrasound (to exclude trauma, retained placenta,
clot evacuation)
▪ Bladder catheter
▪ Use a liquid (0.9% saline, body temperature if possible) to fill the balloon
tamponade – NOT air
▪ Additional vaginal tamponade
▪ Intensive monitoring, antibiotic prophylaxis
▪ Can be left in utero for up to 24 hours
Consensus-based Recommendation 8.E21
Expert consensus Level of consensus +++
Suitable suture materials (large needles, long suture threads) must be kept
in readiness in the operating theatre.
GebFra Science | GuidelineThere has been a recent report on the use of a special gauze
(Celox®) coated with a haemostatic agent (chitosan), originally
developed for emergency treatment and military combat medi-
cine, to successfully manage PPH [74].Consensus-based Recommendation 7.E19
Expert consensus Level of consensus ++
Uterine tamponade – in whatever form – does not preclude other neces-
sary therapeutic options, such as compression sutures [64,75]; the use of
compression sutures is strongly recommended, particularly to treat atony
[75–78].
Consensus-based Recommendation 8.E22
Expert consensus Level of consensus +++
Ligature of the internal iliac artery must only be carried out as a last resort
and only by a surgeon with extensive experience of pelvic surgery.8 Surgical Measures (Compression, Devascular-
isation, Hysterectomy) and Embolisation
8.1 Bridging proceduresConsensus-based Recommendation 8.E20
Expert consensus Level of consensus ++
In the event of the lethal triad consisting of persistent haemorrhage, hae-
morrhagic shock und coagulopathy, the following three-stage approach is
recommended [62]:
▪ Early surgical haemostasis carried out by the attending surgical obste-
trician using a Pfannenstiel incision or median laparotomy, eventeration
of the uterus with cranial traction and uterine compression, and atrau-
matic clamping of the uterine arteries tominimise perfusion. Placement
of uterine compression sutures and application of a uterine tamponade.
▪ Parallel correction of hypovolaemia, temperature, disturbed acid-base
balance and coagulopathy by the anaesthesiologist; if possible, surgery
should then be paused until stabilisation.
▪ Definitive (surgical) treatment of the now haemodynamically stable pa-
tient by a surgeon with the appropriate surgical expertise. If the neces-
sary infrastructure is available, option to perform interventional radio-
logical embolisation of afferent uterine arteries [79,80]. The benefit of
this approach is that it can preserve fertility, as has been described for
large case series [81–84].
390 Schlemba8.2 Uterine compression sutures
The aim of these sutures is to compress the uterus, reduce the
placental adhesion area and tamponade the bleeding site. This ap-
proach is indicated for uterine bleeding after vaginal delivery or
following Caesarean section. At present it is not possible to say
anything about the optimal efficacy of specific types of sutures.
All of the employed methods had high success rates in terms of
preventing hysterectomy which would otherwise have been nec-
essary. The choice of the appropriate suture method depends on
the indication (atony, bleeding from the placental bed, diffuse
bleeding) [85].8.3 Vascular ligatures
In addition to simple ligature of the uterine artery [86] stepwise
uterine devascularisation can also be used for haemostasis. The
technique consists of 5 consecutive steps to ligate the ascending
and descending branches of the uterine arteries and the ovarian
arterial collaterals [87,88].8.4 Postpartum hysterectomyConsensus-based Recommendation 8.E23
Expert consensus Level of consensus +++
Conservative measures to preserve the uterus are only useful if the patient
is haemodynamically stable and does not have life-threatening bleeding
[89,90]. The decision that hysterectomy is indicated must not be delayed
or left too late.
Consensus-based Recommendation 8.E24
Expert consensus Level of consensus +++
Supracervical hysterectomy is the procedure of choice for atony, as the
operating time is significantly shorter and the operation does not lead to
unintended vaginal shortening. Total hysterectomy should be considered
for placental implantation disorders of the lower uterine segment; visu-
alisation of the ureters during this procedure is recommended.
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Relative contraindications for uterus-preserving measures
are:
▪ Extensive abnormally invasive placenta (placenta increta/
percreta) where the placental implantation bed is open, bleed-
ing from the placental implantation bed is resistant to treat-
ment or the implantation bed covers large areas of the uterine
wall.
▪ Non-reconstructable uterine injury
▪ Septic uterusConsensus-based Recommendation 8.E25
Expert consensus Level of consensus ++
During the bridging time to definitive treatment, (bimanual) compression
of the aorta for up to 20minutes may be carried out to avoid unnecessary
blood loss [91,92]. If it is clear that the haemorrhage cannot be controlled
by hysterectomy or is continuing even though hysterectomy has been car-
ried out, the lesser pelvis and abdomen should be packed with sufficient
moistened abdominal cloths.8.5 Arterial catheter embolisationConsensus-based Recommendation 8.E26
Expert consensus Level of consensus +++
Every obstetric department should ascertain whether arterial catheter em-
bolisation can be performed in their facility and the time it takes for this
method to be available and then create the organisational structure which
will determine at what point the patient should be transferred to the inter-
ventional radiology department. The precondition for transfer is that the
patient is haemodynamically stable and does not have massive bleeding.
Consensus-based Recommendation 8.E27
Expert consensus Level of consensus ++
If catheter embolisation is available on site, the radiologist should be noti-
fied early (e.g. when an attempt at haemostasis using uterine compression
sutures is unsuccessful). Because of the range of side effects, medical and
surgical treatment options should be largely exhausted. The time of trans-
fer to the radiology department is also determined by how important it is to
preserve the uterus.
Consensus-based Recommendation 8.E28
Expert consensus Level of consensus +++
Before the patient is transferred, intra-abdominal packing should be con-
sidered as a bridging procedure if the patient has just undergone a hyster-
ectomy procedure to prevent a critical loss of blood during transportation
and contain the bleeding during the sometimes protracted intervention.
Consensus-based Recommendation 8.E29
Expert consensus Level of consensus ++
If the intervention can be planned ahead (e.g., placenta increta/percreta),
endovascular catheters can already be placed preoperatively into the inter-
nal iliac artery on both sides.
Schlembach D et al. Peripartum Haemorrhage, Diagnosis… Geburtsh Frauenheilk 2018; 78: 382Catheter embolisation may be used as a last resort to treat persis-
tent diffuse bleeding in the lesser pelvis after postpartum hyster-
ectomy [93].
9 Haemostasis and Coagulation Management –
Intensive Medical Procedures
9.1 Background
Understanding and recognising the most probable pathophysiol-
ogy of the bleeding is important, as this will offer pointers for dif-
ferent therapeutic approaches. The problem associated with hae-
mostatic management is the difficulty in differentiating between
increased bleeding caused by a major injury and protracted bleed-
ing where the composition of blood has changed (i.e., the normal
capacity of the system to compensate for smaller injuries has
been reversed; this equates to an impairment of the coagulation
system = coagulopathy). It is therefore necessary to distinguish
between:
▪ trauma-induced coagulopathy with shock and massive tissue
trauma
▪ initial “traumatic” haemorrhage caused by tissue trauma, and
▪ initial coagulopathic bleeding.
Impaired coagulation (= coagulopathy) is often an early pathology
of PPH which can occur before dilutional coagulopathy occurs [39,
94].Consensus-based Recommendation 9.E30
Expert consensus Level of consensus +++
The length of time needed to obtain diagnostic findings means that it is
not possible to await the results of diagnostic procedures which differen-
tiate between different coagulopathies (e.g. congenital vs. acquired) be-
fore making treatment decisions. As a rule (if the patientʼs medical history
does not indicate any congenital coagulopathy), it should be assumed that
patients with peripartum or postpartum haemorrhage have an acquired
coagulopathy, unless a surgical cause of haemorrhage can be clearly
identified.It is also important to take account of the fact that, because of
the associated dilution effect and the use of coagulation factors,
every primary mechanical bleeding treated with volume replace-
ment and fresh frozen plasma (FFP) will become coagulopathic if
volume substitution and FFP administration is continued over a
lengthy period [95–97].Consensus-based Statement 9.S6
Expert consensus Level of consensus +++
It is therefore essential that all hospitals with obstetric departments de-
velop a treatment algorithm for peri-/postpartum haemorrhage which is
adapted to the specific conditions in the respective hospital [46,98–101].
The aimmust be to identify haemorrhaging patients early on and describe
the appropriate interdisciplinary surgical, interventional and haemostatic
treatment to manage the bleeding. This algorithm should define the ap-
proach for the treatment process based on the clinical situation and take
account of all available treatment options (pharmacological therapies, in-
terventional procedures, surgical interventions).
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Consensus-based Recommendation 9.E32
Expert consensus Level of consensus +++
GebFra Science | Guideline9.2 Options to treat peri-/postpartum coagulopathic
haemorrhageConsensus-based Statement 9.S7
Expert consensus Level of consensus +++
During active bleeding, any iatrogenic aggravation of the tendency to
bleed (e.g. by administering artificial colloids for volume replacement
which has a strong dilution-related coagulopathic effect, or attempt to
achieve high-normal blood pressure) should be avoided, where possible.
Consensus-based Statement 9.S8
Expert consensus Level of consensus ++
Blood component therapy is currently the standard therapy for haemo-
stasis, either using labile (cellular components, FFP) or stable (lyophilised
factor concentrates) blood products, and should be administered early to
prevent dilutional coagulopathy occurring in addition to the already exist-
ing loss of blood.
Although the data is controversial and prospective randomised studies are
lacking, one or two attempts at treatment with rFVIIa at a dose of 90 µg/kg
BW can be undertaken as a last resort in carefully selected cases if
1. the patient has previously received adequate and appropriate treatment
with other blood products,
2. the other methods used for haemostasis were not sufficiently effective,
and
3. the patient still wants to have other children before undergoing a hys-
terectomy [39,113–116].
Because of the risk of thromboembolism, recombinant FVIIa (NovoSeven®)
should only be given as a last resort [117]. Plasmatic factor concentrations
and platelet numbers should be optimised before rFVIIa is administered
[46].
Consensus-based Statement 9.S10
Expert consensus Level of consensus ++
In summary, the conclusions to be drawn from the currently available data
on haemostatic management recommend
▪ an escalating concept (i.e., a successive step-by-step range of treatment
options) adapted to the respective conditions in each hospital [46, 99,
100],
▪ early administration of tranexamic acid, preferably immediately after
making the diagnosis,
▪ stabilisation of physiological preconditions for coagulation (i.e. pH,
temperature, calcium level) [46,95],Based on the current state of knowledge, fibrinogen plays a key
role. In patients with a history of peri-/postpartum haemorrhage
and patients with peripartum bleeding, plasma fibrinogen con-
centrations should be determined (irrespective of treatment), as
concentrations < 2 g/l could help identify those patients at in-
creased risk of severe PPH [39,46].Consensus-based Recommendation 9.E31
Expert consensus Level of consensus ++
In any case, potentially increased fibrinolytic activity should be treated by
the administration of tranexamic acid (an antifibrinolytic) before the sub-
stitution of fibrinogen (factor concentrate or FFP) is considered [39].
Consensus-based Statement 9.S9
Expert consensus Level of consensus +++
The beneficial effects (lower loss of blood, reduced blood transfusion, in-
creased Hb, lower number of invasive procedures) of administering tranex-
amic acid to treat PPH have since been shown in randomised, controlled
studies of around 2000 patients [102–110].
In 2013 the ESA issued a strong recommendation based onmoderate evi-
dence for the administration of tranexamic acid to treat obstetric bleeding
to reduce blood loss, bleeding duration and the number of transfusions
[46].
There are no reliable data on the use of DDAVP (Minirin®) in obstetrics
which would permit an evidence-based recommendation [111], although
there have been repeated reports of observational studies with positive
outcomes [112]. According to the ESA, DDAVPmay be useful to treat
platelet function disorders resulting from acquired von Willebrand syn-
drome (from drugs, acidosis, hypothermia) [46].
▪ if bleeding persists, viscoelastic test or conventional diagnostic tests to
diagnose the cause of bleeding,
▪ if bleeding persists and substitution is required (if need be, in parallel to
othermechanical forms of treatment), early replacement of coagulation
factors with factor concentrates and/or FFP (fibrinogen should be con-
sidered if dilutional coagulopathy is present, otherwise PCC and F XIII
may be used),
▪ if necessary (i.e. when other approaches are not effective), optimisation
of platelet numbers (target > 100,000/µl for patients with active bleed-
ing requiring transfusion) [46].
Consensus-based Recommendation 9.E33
Expert consensus Level of consensus +++
After the underlying cause of bleeding has been treated, thromboprophy-
laxis must be administered within 24 hours [39]. Because of the reduced
antithrombin activity (absolute activity may even be less than 0.5 kIU/l) in
the majority of women with PPH, an increased risk of thromboembolism is
expected after the bleeding has stopped [118]. After the administration
of individual coagulation factor concentrates or complex preparations (e.g.
PCC), antithrombin activity can be determined on the intensive care unit
and substituted if necessary [119]. The target value is ≥ 80% or ≥ 0.8 kIU/l
[119–121].
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9.3 Anaesthesia-related aspects of managing PPHEscalating regimen of haemostatic therapeutic options to treat PPH (based on recommendations of the S3-guideline 012/019 “Polytrauma/Schwer-
verletztenbehandlung” [Multitrauma/Treatment of Severely Injured Persons], DGAI recommendations on treating severe bleeding and ESA recom-
mendations on treating perioperative haemorrhage) [100,136].
1. Stabilise general conditions (prophylaxis and therapy!) Core temperature ≥ 34 °C (preferably normothermia)
pH ≥ 7.2
ionised Ca++ concentration > 0.9 mmol/l (preferably normocalcaemia)
2. Prevent potential (hyper-) fibrinolysis (always PRIOR to the
administration of fibrinogen and/or FFP!)
Tranexamic acid (Cyklokapron®) initially 1–2 g (15–30mg/kg BW),
repeat as needed
3. Substitution of oxygen carriers RBC administration
Haemostatic target in patients with severe bleeding: Hb ~ 7–9 g/dl
(4.3–5.5 mmol/l) or Hct ~ 30%
4. Substitution of clotting factors (if severe haemorrhage persists)
depending on availability in hospital
FFP ≥ 20 (preferably 30) ml/kg BW
or/and
fibrinogen (Haemocomplettan®) (2–)4(–8) g (30–60mg/kg BW)
Target: ≥ 200mg/dl or ≥ 2.0 g/l
Patients who require (or are anticipated to require) massive trans-
fusion or suffer life-threatening haemorrhagic shock may benefit
from high FFP :RBC ratio of ≥1 :2 or from combined administration
of FFP and factor concentrates.
If required, PCC initially 1000–2500 IU (25 IU/kg BW)
If required, 1–2× FXIII (Fibrogammin® P)E; 1250 IU (15–20 IU/kg BW)
and (if thrombocytopenia is suspected) increased platelet adhesion
to endothelium + release of vonWillebrand factor and FVIII from en-
dothelium/liver sinusoids (→ agonist for vasopressin type 2 receptor)
DDAVP = desmopressin (Minirin®)
0.3 µg/kg BWover a period of 30 minutes (1 vial per 10 kg BWover a period
of 30min)
5. Platelet substitution for primary haemostasis Platelet concentrate (target for haemorrhage requiring transfusion: 100000/µl)
6. If necessary, thrombin burst with platelet and coagulation activation
(consider general haemostatic conditions!)
In individual cases and when all other treatment options have been unsuc-
cessful
rFVIIa (NovoSeven®) if required, initially 90 µg/kg BW
During ongoing bleeding No antithrombin (ATIII) during haemorrhage, may be considered after
administration of PCC and cessation of bleeding
No heparin during haemorrhage
CAUTION: Thrombosis prophylaxis is mandatory within 24 hours after cessation of the pathology causing the bleeding!
Consensus-based Recommendation 9.E34
Expert consensus Level of consensus +++
▪ Maintain or achieve haemodynamic stability and normovolaemia:myocardiac ischaemiawith reduced contractility is often present whenHb values ≤ 6 g/dl
(3.726mmol/l) with or without haemodynamic abnormality (RRsys < 90mmHg and/or RRdia < 50mmHg and/or HR ≥ 115/min) [122,123].
▪ Timely call for expert assistance is recommended for uncontrolled blood loss ofmore than 500ml following vaginal delivery ormore than 1000ml following
Caesarean section and is essential if blood loss is more than 1500ml [29,89,95,124].
▪ For patients receiving regional anaesthesia (spinal anaesthesia, epidural anaesthesia): if blood loss is ≥ 1500–2000ml and there are signs of persistent
bleeding: secure the airway and ensure sufficient oxygen supply; if necessary, performearly intubation after consultationwith the surgeon [125]. If there is
a loss of protective reflexes, endotracheal intubation to secure the airway and ensure sufficient oxygenation must take priority.
▪ Placewide-diameter access points (2× ≥ 16 G) followed by arterial blood pressure measurement, if necessary even before intubation. A wide-diameter
central access (≥ 9 Fr) is recommended [125–128].
▪ Cell saver blood (official recommendations of CMACE, NICE, OAA/AAGBI, ESA): use ofmechanical autotransfusion in patients undergoing elective Caesarean
section (e.g. in cases with placenta increta/percreta) can reduce the administration of allogenic blood postoperatively and the duration of hospital stay [129,
130]. In the emergency setting of PPH the following caveatsmust be taken into consideration: should only be used, after amniotic fluid removal and delivery
of the neonate.
– Cell-saver blood does not contain clotting factors or platelets. Coagulation factors should be substituted to prevent coagulopathy when administering
high transfusion volumes [131].
– Cases of hypotension have been reported following the re-transfusion of cell-saver blood with a leukocyte depletion filter [132].
▪ Target values in haemodynamic therapy
for “healthy” pregnant women and strong bleeding:
– After cord clamping, hypotensive resuscitation until surgical haemostasis is achieved with restrictive fluid therapy [133,134].
– “Normal recapillarisation time” or “palpable radial pulse” are the target values for volume replacement therapy [135,136]
– Goal:MAP > 65mmHg or lower [137] or RRsys ~ 90mmHg [138].
– Target Hb: indication for blood transfusion until surgical haemostasis: 7 g/dl (4.347mmol/l); after surgical haemostasis and successful treatment
of the underlying pathology: 7–9 g/dl (4.347–5.589mmol/l) [23,134,138].
Note: ensure sufficient additional iron supplementation on the ward postoperatively.
▪ Pharmacological thromboprophylaxiswithin 24 hours after the pathology causing the bleeding has been treated [134].
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Consensus-based Recommendation 14.E39
Expert consensus Level of consensus +++
Simulations of haemorrhagic situations must be carried out by an interdis-
ciplinary team at regular intervals; studies have shown that this leads to an
improvement in the management of peri-/postpartum haemorrhage [35,
143].
GebFra Science | Guideline9.4 Rotational thromboelastometry (ROTEM)/
thromboelastography (TEG)
The mean time until the results of standard laboratory parameters
are available in the operating room is at least 45 minutes [139].
Coagulation disturbances can be detected significantly faster with
the viscoelastic test (VET) [139,140].
Currently, two procedures are used for point-of-care (POC) di-
agnostics offering prompt, bedside recognition of clotting disor-
ders based on VET: rotational thromboelastometry (ROTEM, Tem
International GmbH, Munich, Germany) and thromboelastogra-
phy (TEG, Haemonetics, Braintree, MA, USA) [141].
At present there are no class 1 recommendations on the use of
these procedures [46].
10 TransportationConsensus-based Recommendation 10.E35
Expert consensus Level of consensus +++
As transporting a haemodynamically instable patient is a serious risk, any
transportation of such patients as part of the management of PPHmust be
carefully weighed up, quite apart from the organisational conditions at the
facility caring for the patient (or transportation should only be considered
after haemodynamic stabilisation). It is important that the facility transfer-
ring the patient and the facility accepting the patient agree about timing
and staff coverage during transportation of the patient in the run-up to the
patient transfer and record what the two facilities have agreed upon in
writing [142].11 Monitoring after PPHConsensus-based Recommendation 11.E36
Expert consensus Level of consensus +++
Following PPH, individually adapted active monitoring must be carried out
for at least 24 hours.12 DocumentationConsensus-based Recommendation 12.E37
Expert consensus Level of consensus +++
Every event defined as an emergency must be carefully documented. It is
recommended to use the special forms developed for the respective or-
ganisational unit for documentation.13 DebriefingConsensus-based Recommendation 13.E38
Expert consensus Level of consensus +++
Interdisciplinary team debriefing is recommended.
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